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Abstract   
 
The emergence of an unprecedented pandemic SARS-COV-2 caused perplexed in the medical community because of 
a high infection rate and rising mortality among COVID-19 patients. Till now, there is no particular treatment for the 
disease; nevertheless, there is an extensive effort from scientists to find out an immediate therapeutic plan to show 
how to deal with the current situation. One of the solutions currently presented is Convalescence plasma (CP). 
Through this narrative review, we will shed light on CP's efficiency as a therapeutic agent for COVID-19, especially 
there is no proven vaccine or antiviral available up to date. CP could be considered one of the therapeutic approaches, 
but some limitations are still considered before it is established as a therapeutic agent. Along with evaluating CP from 
blood donors, the plasma companies could take future steps by manufacturing a target dose of globulins that contain 
standardized antibody, to reach the terms of health setting administering therapy. 
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Background  
In the time of COVID-19, where coronavirus disease has spread 
Severe respiratory distress symptoms caused by SARS-CoV-2 
are considered a newly emerged beta coronavirus responsible 
for COVID-19. It was first reported in Wuhan, China, in 
December 2019, when around 81 767 cases with 3281 deaths 
have been recorded [1].  Later in March, the WHO proclaimed 
COVID-19 a pandemic disease when it appeared in 
approximately 195 countries [2]. The mechanism of the 
pathogenesis of COVID-19 infection has not been fully clarified 
[3]. There is no proven vaccine or therapy for COVID-19 until 
now. The disease's clinical management protocol recommended 
by WHO focuses on infection prevention, monitoring, and 
detection [4]. Despite the continued lack of accuracy and 
transparency about the COVID-19, scientists are still trying to 
figure out ideal strategies to develop a treatment for COVID-19. 
One of the promising strategies is Convalescent Plasma 
Therapy (CPT). Up to date, using CPT for COVID-9 patients 
has been demonstrated in multiple studies to reduce the 
mortality rate in this unprecedented pandemic situation. The 
investigators in these studies relied on the fact that the CPT is  
 
not a new technique, its efficacy and safety had already been 
tested in other causative agents similar to SARS-CoV-2, despite 
the presence of a few difference between SARS-CoV-2 and 
other types of coronavirus, but the mechanism of CP could be 
the same. [5,6,7]. The issue of using the convalescent plasma 
has grown in importance in light of pandemic COVID-19, 
especially in the absence of availability of vaccine or other 
treatment, so in the current review, we will attempts to discuss 
the desired benefits and some limitation of CPT. 
 
Previous utilization of convalescent plasma  
Convalescent plasma (CP) therapy is known for a long time and 
was used for many viral and bacterial diseases. Previously CP 
used to treat patients with various viral infections, such as 
treating the Spanish flu in 1918, H1N1 infection in 2009, Ebola 
patients in 2014, and Middle East Respiratory Syndrome 
(MERS) in 2015 [8,9,10]. Thereby, CP was suggested as one of 
the therapeutic options for COVID‐19 patients [11]. 
     The CPT mechanism is based on plasma transfusion from 
recovered individuals (Who are harmful to COVID‐19) to 
patients with COVID-19 [12,13]. This transfusion is considered 
as a type of passive immunity, whereas the plasma transfused 
from patients recovered to patients exposed to the same virus 
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This therapy's efficacy has been associated with the 
concentration of NAbs in plasma from recovered donors [16]. 
The neutralizing antibodies against SARS-CoV-2 that has been 
isolated from donors may serve as a promising intervention to 





Donors of CP should fulfill the standard eligibility requirements 
[18], in accordance with the National Guide on Preparation, in 
addition to following the recommendations from an accredited 
agency such as WHO. Multiple published studies have 
discussed CP antibodies' ability to viremia clearance, some of 
these studies support using CPT for COVID-19, but before 
starting the process of plasma transfusion, all precaution rules 
should be applied strictly [19,20].  
     For instance, Sudan is one of the developing countries that 
struggle against the spreading of COVID-19. One of the 
Sudanese studies reported the benefits of using convalescent 
plasma to treat COVID-19 symptomatic patients. This study has 
mentioned that specific criteria should be followed for both 
patient and donor before starting the process of transfusion. One 
of the CP transfusion criteria from a donor, the donor, should be 
free from SARS-CoV-2 infection at the time of plasma 
transfusion. On the other hand, one of the most important CP 
transfusion criteria to a patient is that the patient should have a 
clear symptomatic and confirmed diagnosis for COVID-19 
depending on the official Sudanese therapeutic protocol for 
COVID -19. Furthermore, this study recommended using CPT 
in COVID-19 Sudanese patients at least currently is considered 
an available costless therapeutic option, especially all other 
COVID-19 therapeutics alternatives still under investigation 
studies [21]. 
     Neutralizing antibodies in donor Convalescent sera could be 
used for critical COVID-19 patients as recommended in one of 
the previous issues by the Food and Drug Administration 
[22,23,24]. However, the similarity between some human 
amino acid sequences with SARS-CoV-2 sequence could 
unintentionally way induce the autoimmune system [25]. 
Hence, a rapid vaccination strategy is needed to study 
interference between viral particles and human molecules to 
avoid an undesired self-immunity reaction, especially for those 
who suffer from previous medical history with autoimmune 
disease. Up to date, a few original practical studies used CPT 
for COVID-19 patients, but noteworthy still, the validation of 
the efficacy of CP is a controversial issue between supporters 
and opponents. Despite this, some reports reveal less 
hospitalization and a low mortality rate among patients who 
have been given convalescent plasma [26]. 
 
Challenges facing the use of convalescent plasma  
Dante Mário and his colleagues had mentioned that there are 
some challenges when we were thinking of using convalescent 
plasma therapy for COVID -19 patients. Some of these 
challenges are:-  
a. Is the convalescent plasma transfusion being more 
protective if compared with other antiviral treatments?   
b. Which one is more effective for patients, plasma from 
donors who have no symptoms or plasma from donors 
with symptoms?  
c. What is the best time to transfuse plasma to COVID-19 
patients, in other words, early-stage or late-stage? 
     Some previous studies have also mentioned that there are 
expected complications accompanied by plasma transfusions, 
such as circulatory overload, anaphylactic reactions, and 
alloimmunization [27]. These are logical questions that need to 
be answered before starting accrediting plasma as an acceptable 
treatment for COVID-19. 
 
The current status of therapeutic efforts made with 
COVID-19 
Until the time of writing the current manuscript, the medical 
Scientists are working day and night to find an effective and 
suitable vaccine for controlling the deadly COVID-19.   Most 
Vaccine clinical trials platforms are done in developed 
countries, such as the USA, UK, Germany, Russia, and China. 
It seems there is an unprecedented race between these countries, 
which country would be the first one to produce an effective 
and safe COVID-19 vaccine for the entire world. Instead of 
racing between vaccine production companies, it would be 
better if there are information exchange and collaboration to 
help reach wisdom decision regarding COVID-19 [28].   
     Global cooperation will help avoid and repeat the mistakes 
made at the beginning of the COVID-19 crisis due to a lack of 
information transparency [29].   However, till that time, when 
the effective and trust vaccine appears and could apply 
confidently for patients, CPT is Considered an optimal and 
available option for COVID-19. 
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Conclusion  
To sum up, based on the previously published data, the CPT 
could be an efficient option, at least in the current time, to 
minimize the morbidity and mortality rate of patients with 
COVID-19. However, the extreme benefit of using CPT for 
COVID-19 still needs tremendous investigation. As it is 
recommended, it would be better if used a well-designed study 




ARDS: Acute Respiratory Distress Syndrome; COVID-19: 
Corona Virus Disease of 2019; CP: Convalescence Plasma; 
CPT: Convalescent Plasma Therapy; FDA: Food and Drug 
Administration; HI1N1: Influenza A virus subtype; MERS: 
Middle East Respiratory Syndrome; Nabs: Neutralizing 
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